INTEROFFICE MEMORANDUM

DATE: September 27, 2013

TO: County Health Department Directors/Administrators
County Health Department Medical/Nursing Directors
County Health Department HIV/AIDS Medical Providers
County Health Department AIDS Drug Assistance Program Managers
County Health Department Pharmacists
HIV/AIDS Program Coordinators

FROM: Anna M. Likos, MD, MPH
Division Director, Disease Control and Health Protection

SUBJECT: Addition to ADAP Formulary - Dolutegravir (Tivicay®)

FOR INFORMATIONAL ONLY: New Antiretroviral approved by FDA

Dolutegravir (Tivicay®) has been added to the ADAP Formulary.

On August 12, 2013, FDA approved dolutegravir (Tivicay®), a new antiretroviral, integrase inhibitor, to treat HIV-1 infection. Dolutegravir (Tivicay®) is approved for use in treatment naïve adults, treatment experienced adults (including those with prior integrase strand inhibitor exposure), treatment naïve and treatment experienced children, ages 12 and older (weighing at least 40 kilograms), but who have never taken other integrase strand transfer inhibitors (INSTI-naïve).

Dolutegravir is an integrase strand transfer inhibitor (INSTI) that interferes with the action of the enzyme integrase, required for HIV's genetic material to integrate into the host cell's DNA and multiply. Dolutegravir is the 2nd approved integrase inhibitor.

Clinical trials have shown dolutegravir-containing regimens to be effective in reducing viral loads. Common side effects included insomnia and headache. Serious side effects include hypersensitivity reactions and abnormal liver function in participants co-infected with hepatitis B and/or C. Advice on monitoring patients for serious side effects is included in the attached label.

Dose: The 50 mg tablet is to be taken once daily (without regard to meals) in combination with other antiretroviral drugs in adult patients, treatment naïve or treatment experienced and INSTI-naïve.

INSTI-experienced adults with certain resistance mutations should be dosed at 50 mg twice daily.

Children ≥ 12y/o and wt. ≥ 40 kg and tx naïve or tx-experienced INSTI-naïve: 50 mg once daily

USE IN SPECIFIC POPULATIONS

Pregnancy: Dolutegravir is labeled "Pregnancy Category B" and should be used during pregnancy only if clearly needed.

Hepatic Impairment: Dolutegravir is appropriate for treatment of patients with mild or moderate hepatic impairment, but is not recommended for use in patients with severe hepatic impairment (Child-Pugh Score "C").

Renal Impairment: Dolutegravir is appropriate for treatment-naïve or treatment-experienced and INSTI-naïve patients with mild to severe renal impairment. Use with caution in INSTI-experienced patients with severe renal impairment, decreased dolutegravir concentrations could result in loss of therapeutic effect and development of resistance to dolutegravir or other coadministered antiretroviral agents.

Contraindications: Use of dolutegravir with dofetilide is contraindicated due to a risk of increased dofetilide plasma concentrations potentiating serious and/or life-threatening events.

Metformin levels are increased by dolutegravir; monitor closely on starting or stopping dolutegravir.

For additional information, please find the link below for the package insert on dolutegravir (Tivicay®).

http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63df5af3-b8ac-4e76-9830-2dbb340af922

Please direct any questions to Jeffrey Beal, MD, AAHIVS, Medical Director, HIV/AIDS and Hepatitis Section at (850) 519-3734 or by email at *Jeff_Beal@doh.state.fl.us*.

JB/aef

cc: Celeste Philip, MD, MPH, Interim Deputy Secretary for Health
R. S. Whisenhunt, Chief, Bureau of Communicable Disease
Sherry Riley, Administrator, HIV/AIDS and Hepatitis Section
Jeffrey Beal, MD, AAHIVS, Medical Director, HIV/AIDS and Hepatitis Section
Brandon Brantley, PharmD, Chief, Bureau of Public Health Pharmacy
Ryan White Part A Grantees
Ryan White Part B Lead Agencies
Ryan White Part C Grantees